Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

Interventions

DRUG: Selumetinib
DRUG: Docetaxel
DRUG: Placebo
DRUG: Pegylated G-CSF

Sponsor

AstraZeneca